drugset
drugset / Trial / NCT05213143

The Safety and Efficacy of Lurasidone In Subjects With Schizophrenia Switched From Olanzapine

NCT05213143 ↗

Phase 4 Terminated 13 enrolled Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

An open-label, single-arm and multi-center study for 16 weeks

Timeline

Start
2021-12-30
Primary completion
2022-11-18
Completion
2022-11-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Lurasidone Small molecule 40 mg Oral
Subject Lurasidone Small molecule 80 mg Oral

Indications

schizophrenia